GUIDANT ACS Rx MULTI-LINK HAS 70% U.S. STENT MARKET DOLLAR VOLUME; EVEREST MEDICAL ATTRIBUTES 10% OF FOURTH-QUARTER VOLUME TO GUIDANT VASOVIEW BUSINESS
This article was originally published in The Gray Sheet
Sales of Guidant's ACS Rx Multi-Link stent, launched on Oct. 2, topped $200 mil. in the fourth quarter of 1997, the company reported Feb. 3. According to Guidant President and CEO Ronald Dollens, who spoke the same day at a Piper Jaffray investor conference in New York City, the product now accounts for roughly 70% of the dollar volume and 60% of the unit volume of a U.S. stent market that is rapidly approaching an estimated $1 bil.
You may also be interested in...
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.
Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.